Lab to Lives

Jakob Juul Rasmussen: Zero cost technology - transforming how smaller companies oversee their assets

Season 1 Episode 4

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 45:29

Send us Fan Mail

Sam and Ivanna speak to Jakob Juul Rasmussen about the stubborn prevalence of paper in clinical trials, especially in small pharmaceutical and biotech companies. Paying money up front, covering the implementation and license costs and building up internal IT functions can be prohibitive for small pharmaceutical and biotech companies. This leads many companies to outsource their entire IT landscape to CROs. As a result, control over assets becomes complicated and cumbersome, as your clinical data risks being stored in different applications with multiple data models applied.  Standard configuration is helping bridge the gap, but compliance requirements from authorities for both internal and CRO-maintained software are unchanged. Jakob suggests a radical third way of getting the set of applications needed to run the business of any biotech or pharmaceutical company, without resorting to paper or complete outsourcing, transforming both how technology companies deliver IT solutions and how IT is anchored with the sponsor companies. 

“Small companies really want to focus on science and just have the necessary tools to provide the best science”

  • Jakob Juul Rasmussen

Notes

Visit Labtolives.com

Do you want to try the quiz from this episode? Find the link on our LinkedIn profile: https://www.linkedin.com/company/labtolives/ 

Would you like to join the show as a guest or collaborator? Find out how on our website: https://www.labtolives.com/ 


Support the show


________
Reach out to Ivanna Rosendal

Join the conversation on our LinkedIn page

Visit www.labtolives.com 


Hosts

Alexander Booth aka the MedTech Guy

Dimitri Borisevich aka the start-up Guy

Ivanna Rosendal aka the R&D pharma Gal